205 related articles for article (PubMed ID: 34137077)
1. Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019.
Hester LL; Gifkins DM; M Bellew K; Vermeulen J; Schecter JM; Strony J; Dishy V; Weiss BM
Eur J Haematol; 2021 Oct; 107(4):428-435. PubMed ID: 34137077
[TBL] [Abstract][Full Text] [Related]
2. Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement.
Oubari S; Naser E; Papathanasiou M; Luedike P; Hagenacker T; Thimm A; Rischpler C; Kessler L; Kimmich C; Hegenbart U; Schönland S; Rassaf T; Reinhardt HC; Jöckel KH; Dürig J; Dührsen U; Carpinteiro A
Eur J Haematol; 2021 Oct; 107(4):449-457. PubMed ID: 34185342
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis.
Hari P; Lin HM; Asche CV; Ren J; Yong C; Luptakova K; Faller DV; Sanchorawala V
Amyloid; 2018 Mar; 25(1):1-7. PubMed ID: 29303358
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases.
Dispenzieri A; Zonder J; Hoffman J; Wong SW; Liedtke M; Abonour R; D'Souza A; Lee C; Cote S; Potluri R; Ammann E; Tran N; Lam A; Nair S
Amyloid; 2023 Jun; 30(2):161-168. PubMed ID: 36282014
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias.
Kourelis TV; Kumar SK; Go RS; Kapoor P; Kyle RA; Buadi FK; Gertz MA; Lacy MQ; Hayman SR; Leung N; Dingli D; Lust JA; Lin Y; Zeldenrust SR; Rajkumar SV; Dispenzieri A
Am J Hematol; 2014 Nov; 89(11):1051-4. PubMed ID: 25111004
[TBL] [Abstract][Full Text] [Related]
6. History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis.
Kharoubi M; Bézard M; Galat A; Le Bras F; Poullot E; Molinier-Frenkel V; Fanen P; Funalot B; Moktefi A; Lefaucheur JP; Abulizi M; Deux JF; Lemonnier F; Guendouz S; Chalard C; Zaroui A; Audard V; Bequignon E; Bodez D; Itti E; Hittinger L; Audureau E; Teiger E; Oghina S; Damy T
ESC Heart Fail; 2021 Dec; 8(6):5501-5512. PubMed ID: 34714605
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.
Hasib Sidiqi M; Gertz MA
Blood Cancer J; 2021 May; 11(5):90. PubMed ID: 33993188
[TBL] [Abstract][Full Text] [Related]
8. A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year.
Carter JP; Foard D; Rannigan L; Aliaz K; Mahmood S; Sachchithanantham S; Fontana M; Quarta C; Martinez De Azcona Naharro A; Youngstein T; Rezk T; Wechalekar A; Whelan C; Lachmann H; Hawkins P; Gillmore J; Lane T
Amyloid; 2017 Mar; 24(sup1):72-73. PubMed ID: 28434320
[No Abstract] [Full Text] [Related]
9. [Multisystemic amyloidosis. Clinical study of 39 patients in Lebanon].
Saba M; Tohmé A; Abadjian G; Haddad F; Ghayad E
Presse Med; 2005 May; 34(9):640-6. PubMed ID: 15988337
[TBL] [Abstract][Full Text] [Related]
10. Timing and co-occurrence of symptoms prior to a diagnosis of light chain (AL) amyloidosis.
Singh A; Szabo A; Lian Q; Pezzin L; Sparapani R; D'Souza A
Blood Cancer J; 2024 May; 14(1):61. PubMed ID: 38796476
[TBL] [Abstract][Full Text] [Related]
11. Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis.
Schulman A; Connors LH; Weinberg J; Mendelson LM; Joshi T; Shelton AC; Sanchorawala V
Eur J Haematol; 2020 Oct; 105(4):495-501. PubMed ID: 32564450
[TBL] [Abstract][Full Text] [Related]
12. The use of serum free light chain dimerization patterns assist in the diagnosis of AL amyloidosis.
Gatt ME; Kaplan B; Yogev D; Slyusarevsky E; Pogrebijski G; Golderman S; Kukuy O; Livneh A
Br J Haematol; 2018 Jul; 182(1):86-92. PubMed ID: 29767409
[TBL] [Abstract][Full Text] [Related]
13. Fundamentals of Light Chain Cardiac Amyloidosis: A Focused Review.
Latif A; Lateef N; Razzaq F; Kapoor V; Ahsan MJ; Ashfaq M; Iftikhar A; Anwer F; Holmberg M; William P
Cardiovasc Hematol Disord Drug Targets; 2020; 20(4):274-283. PubMed ID: 33256586
[TBL] [Abstract][Full Text] [Related]
14. Baseline ECG Features and Arrhythmic Profile in Transthyretin Versus Light Chain Cardiac Amyloidosis.
Cappelli F; Vignini E; Martone R; Perlini S; Mussinelli R; Sabena A; Morini S; Gabriele M; Taborchi G; Bartolini S; Lossi A; Nardi G; Marchionni N; Di Mario C; Olivotto I; Perfetto F
Circ Heart Fail; 2020 Mar; 13(3):e006619. PubMed ID: 32164434
[No Abstract] [Full Text] [Related]
15. Immunoglobulin Light Chain Amyloidosis Presenting as Inferior Vena Cava Thrombosis.
Axentiev A; Rozik M; Slama E; Setya V
Am Surg; 2023 Jun; 89(6):2788-2790. PubMed ID: 34743583
[TBL] [Abstract][Full Text] [Related]
16. Serum Hevylite
Yogev D; Pick M; Slyusarevsky E; Pogrebijski G; Pickin A; Gatt ME
Int J Lab Hematol; 2021 Jun; 43(3):418-425. PubMed ID: 33455086
[TBL] [Abstract][Full Text] [Related]
17. Amyloidosis: a case series and review of the literature.
Senecal JB; Abou-Akl R; Allevato P; Mazzetti I; Hamm C; Parikh R; Woldie I
J Med Case Rep; 2023 Apr; 17(1):184. PubMed ID: 37081462
[TBL] [Abstract][Full Text] [Related]
18. [AL amyloidosis, from diagnosis to treatment].
Villesuzanne C; Jaccard A; Nicol M
Rev Prat; 2020 Dec; 70(10):1137-1141. PubMed ID: 33739663
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.
Gertz MA
Blood Cancer J; 2018 May; 8(5):44. PubMed ID: 29795248
[TBL] [Abstract][Full Text] [Related]
20. A cross-sectional study of patient-reported outcomes and symptom burden using PROMIS and PRO-CTCAE measures in light chain amyloidosis.
D'Souza A; Szabo A; Akinola I; Finkel M; Flynn KE
Qual Life Res; 2023 Jun; 32(6):1807-1817. PubMed ID: 36738402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
